Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bardoxolone Methyl Body Composition Study in Stage 4 CKD and T2DM
NCT01655186Phase 2Withdrawn
- Sponsor
- Biogen
- Start
- Sep 2012
- Primary completion
- Oct 2012
- Modality
- Classical Binding Small Molecules
01
Overview
A Phase 2 trial of bardoxolone methyl in chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), sponsored by Biogen. Planned start Sep 2012; status: withdrawn.
02
Drugs
bardoxolone methyl
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01655186.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01655186.